RxDoctor Payments Data

Viola Anderson, MD

Internal Medicine · Texas City, TXNPI 1700870540

Payments from drug & device makers

$841in general payments, 2019–2025

Across 41 payments — averaging $20.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$291
  • AstraZeneca$84
  • Exact Sciences$77
  • GSK$68
  • Novo Nordisk$55
  • Boehringer Ingelheim$41
  • plus $225 from 9 others

What the payments were for

  • Food & beverage$841100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$841 in reported general payments places this provider in the 65th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$44,074
Medicare patients
111
Services billed
1,043

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol69$82,349
EliquisApixaban47$60,261
OzempicSemaglutide37$51,876
RybelsusSemaglutide14$28,232
JardianceEmpagliflozin25$27,460
JanuviaSitagliptin Phosphate22$25,742
TrulicityDulaglutide15$18,903
BrilintaTicagrelor12$14,379
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog26$10,057
Atorvastatin Calcium602$6,978
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$6,271
Losartan Potassium493$5,762
Breo ElliptaFluticasone/Vilanterol13$4,709
Levemir FlexpenInsulin Detemir22$3,420
Albuterol Sulfate HfaAlbuterol Sulfate84$2,934

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$84$96,72881 claims
Novo NordiskOzempic, Rybelsus$55$80,10851 claims
Boehringer IngelheimJardiance$41$27,46025 claims
MerckJanuvia$21$25,74222 claims
Lilly USA, LLCTrulicity$32$18,90315 claims
GSKBreo Ellipta$68$4,70913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Texas City

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →